The FDA approved a new formulation of olanzapine for schizophrenia in adults. This subcutaneous injectable form is administered monthly. The new formulation eliminates the need for loading doses and post-injection delirium/sedation syndrome monitoring, addressing issues previously associated with other long-acting olanzapine products.
Olanzapine has been a foundational treatment option for schizophrenia for over 30 years, but adherence remains a challenge. The new injectable formulation achieves therapeutic blood levels without oral cotreatment or booster injections. The approval was supported by the phase III SOLARIS trial, which demonstrated superiority over placebo in reducing PANSS total scores. Key secondary endpoints also showed improvement. No PDSS cases occurred during the trial. The new injectable is available in doses matching the approved oral olanzapine strengths. Like other antipsychotics, the product carries a boxed warning regarding increased mortality risk in elderly patients with dementia-related psychosis. Potential risks include metabolic changes, tardive dyskinesia, and orthostatic hypotension. Common adverse events observed in the SOLARIS trial were consistent with oral olanzapine, including increased weight, somnolence, headache, and constipation, alongside injection site reactions.”}